ΣΦ-1403

ΣΦ-1403 is an internal development code for a pharmaceutical product being developed by Sigmapharm Laboratories. According to the company's pipeline, the product is being prepared for regulatory submission via either the Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) pathways. The specific active ingredient, therapeutic indication, and mechanism of action have not been publicly disclosed. The product is categorized by the sponsor as having "Barrier-to-Entry Properties," which may include formulation challenges, patent-litigation challenges, bioavailability challenges, or stability challenges. Sigmapharm Laboratories specializes in the development of unique generic and branded products, particularly those with complex delivery systems or significant regulatory hurdles.